Clearmind Medicine Advances Fight Against Cocaine Addiction With Publication of US Patent Application for its Non-Hallucinogenic Neuroplastogen MEAI Therapy
Clearmind Medicine Inc. recently announced the publication of a US patent application expanding coverage of its non-hallucinogenic proprietary compound, 5-methoxy-2-aminoindane (MEAI), for the treatment of cocaine addiction.
The application strengthens Clearmind’s growing intellectual property portfolio and reinforces MEAI’s potential to address a major unmet medical need. Cocaine use disorder affects millions worldwide and currently has no FDA-approved pharmacological treatment. The global market for cocaine addiction treatment is estimated at $1.36 billion in 2025 and is projected to grow to $2.03 billion by 2032, highlighting the urgent demand for new and effective solutions.
MEAI is a novel, non-hallucinogenic neuroplastogen designed to modulate serotonin and dopamine pathways, potentially reducing cravings and supporting long-term recovery. This approach could offer a safer, scalable alternative to existing behavioral interventions.
“Securing protection for MEAI’s potential use in cocaine addiction supports our broader strategy to build a robust pipeline of non-hallucinogenic neuroplastogens,” said Adi Zuloff-Shani, Ph.D., CEO of Clearmind Medicine. “We believe this patent filing represents another key step in positioning Clearmind as a leader in next-generation addiction therapeutics.”
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.” For further information visit: https://www.clearmindmedicine.com.
Total Page Views: 441
